(Q51729130)

English

Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.

scientific article published on 15 April 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/24746000

Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/24746000

0 references

chronic obstructive pulmonary disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Menno M van der Eerden

object named as

Menno M van der Eerden

10

0 references

3

object named as

Jan A J W Kluytmans

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/24746000

author name string

Sevim Uzun

1

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/24746000

Remco S Djamin

2

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/24746000

Paul G H Mulder

4

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/24746000

Nils E van't Veer

5

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/24746000

Anton A M Ermens

6

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/24746000

Aline J Pelle

7

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/24746000

Henk C Hoogsteden

8

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/24746000

Joachim G J V Aerts

9

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/24746000

publication date

15 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/24746000

The Lancet. Respiratory medicine

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/24746000

2

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/24746000

5

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/24746000

361-368

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/24746000

Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of action and clinical application of macrolides as immunomodulatory medications

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Azithromycin for prevention of exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibiotic prevention of acute exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of 6 Months of Erythromycin Treatment on Inflammatory Cells in Induced Sputum and Exacerbations in Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Erythromycin and common cold in COPD

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors associated with bronchiectasis in patients with COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors associated with change in exacerbation frequency in COPD

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of bronchial colonisation on airway and systemic inflammation in stable COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug interactions with azithromycin and the macrolides: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970019-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-2600(14)70019-0

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/24746000

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/24746000

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51729130&oldid=2162868244"